0001104659-23-122092.txt : 20231129
0001104659-23-122092.hdr.sgml : 20231129
20231129171449
ACCESSION NUMBER: 0001104659-23-122092
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231127
FILED AS OF DATE: 20231129
DATE AS OF CHANGE: 20231129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WG Biotech ApS
CENTRAL INDEX KEY: 0001753193
STATE OF INCORPORATION: G7
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38650
FILM NUMBER: 231453263
BUSINESS ADDRESS:
STREET 1: RUNGSTED STRANDVEJ 113
CITY: RUNGSTED KYST
STATE: G7
ZIP: 2960
BUSINESS PHONE: 45-45-17-77-77
MAIL ADDRESS:
STREET 1: RUNGSTED STRANDVEJ 113
CITY: RUNGSTED KYST
STATE: G7
ZIP: 2960
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc.
CENTRAL INDEX KEY: 0001722964
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474619612
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 230 PARK AVENUE
STREET 2: SUITE 3350
CITY: NEW YORK
STATE: NY
ZIP: 10169
BUSINESS PHONE: 212-847-9841
MAIL ADDRESS:
STREET 1: 230 PARK AVENUE
STREET 2: SUITE 3350
CITY: NEW YORK
STATE: NY
ZIP: 10169
4
1
tm2330155-5_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-11-27
0
0001722964
Y-mAbs Therapeutics, Inc.
YMAB
0001753193
WG Biotech ApS
RUNGSTED STRANDVEJ 113
RUNGSTED KYST
G7
2960
DENMARK
1
0
0
0
0
Common Stock
2023-11-27
4
P
0
62516
5.4869
A
4342721
D
Common Stock
2023-11-28
4
P
0
30671
5.8125
A
4373392
D
This transaction was executed in multiple trades at prices ranging from $5.38 to $5.60. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $5.51 to $6.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Johan Wedell-Wedellsborg is the majority owner of WG Biotech ApS and has sole voting and dispositive power over the shares of the Issuer held by WG Biotech ApS. Mr. Wedell-Wedellsborg serves as a director of the Issuer. In connection therewith, WG Biotech ApS may be deemed to be a director by deputization of the Issuer solely for purposes of Section 16(a) of the Exchange Act. As a result, WG Biotech ApS is listed as a "Reporting Person" in Item 1 and the "Director" box is marked in Item 5 of this Form 4. This filing shall not be deemed an admission by Reporting Person on this Form 4 that such person is a director of the Issuer by deputization.
WG Biotech ApS by /s/ Johan Wedell-Wedellsborg
2023-11-29